For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  Tirzepatide
Weight & Metabolicapproved

Tirzepatide

Mounjaro
Weight & Metabolic · CAS 2023788-19-2
ASK VERA ABOUT THIS ↗BUY NOW ↗
Category
Weight & Metabolic
Evidence grade
A
PubMed records
2,288
Female-tagged
443
Sex-analysis
5
CAS
2023788-19-2
A
Evidence grade A, Approved indication with 443 indexed studies that included female subjects. How grades work →
Female evidence: Direct
Tirzepatide: of 2,288 PubMed records, 443 are tagged as including female subjects and 5 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-17. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

Tirzepatide is a dual agonist of the GIP and GLP-1 receptors, engineered to engage both incretin pathways with a single molecule. Through this combined activity it enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite through central pathways. It has been approved for type 2 diabetes and weight management, and its clinical program enrolled large trial populations.

In research models, tirzepatide has been studied for its effects on glycemic regulation, body-weight and energy-balance endpoints, and the downstream metabolic pathways engaged by incretin signaling. Investigators characterizing dual-incretin pharmacology have used it as a reference material against single-receptor agonists.

One feature relevant to a metabolic and hormonal catalog is that tirzepatide carries a documented interaction with oral contraceptives that many peptide sources omit. This interaction, and the degree to which trial evidence has been reported for women, is exactly the kind of open research question our evidence review tracks by recording how many of the underlying studies included women.

Summary

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and weight management. Its trials enrolled large numbers of women, and it carries a specific, important interaction with oral contraceptives that most peptide sources omit.

Evidence in women

Menstrual cycle
Unstudied
Appetite and nausea effects have not been evaluated across menstrual cycle phases.
Pregnancy & lactation
Contraindicated
Not recommended in pregnancy; discontinue before a planned pregnancy per label. Effects in lactation are not established.
Hormonal interactions
Evidence
The label warns that tirzepatide may reduce the effectiveness of ORAL hormonal contraceptives, likely via delayed gastric emptying. A non-oral contraceptive method, or a backup barrier method, is advised for 4 weeks after starting and after each dose increase. This is a genuinely important, often-omitted fact for women.
Perimenopause & menopause
No evidence
No dedicated trials in perimenopausal weight change; broad female enrollment spans this age range but is not stratified by menopausal status.
Sex differences
Evidence
In the indexed literature, many studies included women; some analyses report women achieving greater weight loss than men, though few reported sex-stratified outcomes.

Mechanism

A dual agonist of the GIP and GLP-1 receptors that enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite through central pathways.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Per approved label; titrated. Reported here for reference, not as advice.
Routessubcutaneous
Female-specific dosingNot established

Contraindications: personal/family history of medullary thyroid carcinoma; MEN 2; pregnancy

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

nauseavomitingdiarrheadecreased appetitedelayed gastric emptying

Tirzepatide reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for Tirzepatide

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from Tirzepatide's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is Tirzepatide?

Tirzepatide, also known as Mounjaro, is a research compound in our weight metabolic category. Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and weight management.

Is Tirzepatide studied in women?

Tirzepatide: of 2,288 PubMed records, 443 are tagged as including female subjects and 5 carry a sex-analysis tag. We grade this direct female evidence: at least one record carries a sex-analysis tag, so some findings are drawn from women rather than borrowed from mixed or male data. See how we read the evidence.

Has Tirzepatide been studied during pregnancy or breastfeeding?

Contraindicated. Not recommended in pregnancy; discontinue before a planned pregnancy per label. Effects in lactation are not established. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does Tirzepatide have, and why?

Tirzepatide carries evidence grade A. Approved indication with 443 indexed studies that included female subjects.. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for Tirzepatide?

No. A female-specific dose for Tirzepatide is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is Tirzepatide administered in research?

In the published literature, Tirzepatide is administered via subcutaneous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for Tirzepatide?

Effects reported in the research literature include nausea, vomiting, diarrhea, decreased appetite, delayed gastric emptying. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

What is the CAS number for Tirzepatide?

The CAS registry number for Tirzepatide is 2023788-19-2. It is also referred to as Mounjaro, Zepbound, GLP-2 TZ, GIP/GLP-1 agonist. Use it to confirm identity against a Certificate of Analysis.

How should Tirzepatide be stored and handled?

Tirzepatide sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy Tirzepatide for research?

For laboratory research use, Tirzepatide is available from our research-use partner, Aurevena Research. Applying code research15 takes 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Buy Tirzepatide at Aurevena Research
Research-use supplier: Tirzepatide is available from our research-use vendor for laboratory use. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Buy now →

Citations (PMID)

34370970 · 35658024

Related peptides

4X Blend (Methionine / Choline / Carnitine / Dexpanthenol)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
5-Amino-1MQD
5-Amino-1MQ: of 3 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.
8X Blend (L-Carnitine / L-Arginine / Methionine / Inositol / Choline / B6 / B5 / B12)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
AdipotideD
Adipotide: of 4 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.